Verve Therapeutics Soars 26.69% on Positive Heart-2 Trial Data

On April 14, 2025, Verve Therapeutics' stock surged by 26.69% in pre-market trading, driven by the announcement of positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, a single-dose base editing treatment targeting PCSK9 for cardiovascular disease.

Verve Therapeutics has reported encouraging initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, a single-dose base editing treatment targeting PCSK9 for cardiovascular disease. The trial included 14 participants with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). Key findings across three dose cohorts (0.3, 0.45, and 0.6 mg/kg) showed a mean LDL-C reduction of 53% and a maximum reduction of 69% in the 0.6 mg/kg cohort. The treatment was well-tolerated, with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets.

The company plans to announce final dose escalation data in the second half of 2025, initiate Phase 2 trials, and receive Eli Lilly's decision on their PCSK9 program opt-in. Current funding is expected to last until mid-2027. The positive results from the Heart-2 trial position VERVE-102 competitively against existing PCSK9 inhibitors that require regular dosing, addressing the significant medication adherence problem in cardiovascular disease management.